Johnson & Johnson Covid-19 vaccine benefits 'far outweigh' risks: CDC
The benefits of the Johnson & Johnson Covid-19 vaccine far outweigh its potential risks amid an ongoing review of reports of a rare neurological disorder, according to an advisory panel to the US Centers for Disease Control and Prevention (CDC) on Thursday. There have been 8.1 cases of Guillain-Barre syndrome per 1 million doses, which is higher than expected in the general population and close to eight times the rate seen in Pfizer's and Moderna's shots, according to data presented at a meeting of CDC's Advisory Committee on Immunization Practices on Thursday. Guillain-Barre is a neurological disorder in which the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis, according to the US Food and Drug Administration (FDA). The data came after the US Food and Drug Administration (FDA) announced a new warning on July 12 for the Johnson & Johnson shot after preliminary reports of Guillain-Barre syndrome in some recipien